SCHEMBL375617

SCHEMBL375617

CN(C)CC(C)(C)C[NH]

nearest known ligand 0.00

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL227850 0.79 CYP3A4 (0.34)
SCHEMBL736531 0.71
SCHEMBL19199690 0.69
SCHEMBL3853920 0.69
SCHEMBL172997 0.69 CYP3A4 (0.31)
SCHEMBL2272593 0.69
SCHEMBL17975839 0.69
SCHEMBL363890 0.69
SCHEMBL16387894 0.69
SCHEMBL1620302 0.69

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-110950848-A Synthesis and application of novel amino pyrazole derivatives 徐诺药业 2020-04-03 CN claimed
US-8921424-B2 Histone deacetylase inhibitors, process for preparation and uses thereof ZHEJIANG HISUN PHARMACEUTICAL CO. LTD. (CN) 2014-12-30 US claimed
EP-2208721-B1 HISTONE DEACETYLASE INHIBITOR, COMPOSITION AND USE THEREOF ZHEJIANG HISUN PHARM CO LTD (CN) 2013-12-25 EP claimed
EP-2287156-B1 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders NOVARTIS AG (CH) 2013-05-29 EP claimed
EP-1660458-B1 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS NOVARTIS AG (CH) 2012-01-25 EP claimed
US-20110218221-A1 NOVEL HISTONE DEACETYLASE INHIBITORS, PROCESS FOR PREPARATION AND USES THEREOF ZHEJIANG HISUN PHARMACEUTICAL CO., LTD. (CN) 2011-09-08 US claimed
US-20110098280-A1 2,4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS NOVARTIS AG (CH) 2011-04-28 US claimed
EP-2287156-A1 2,4-Di(phenylamino)-pyrimidines useful in the treatment of neoplastic diseases, inflammatory and immune system disorders Novartis AG (CH) 2011-02-23 EP claimed
US-7893074-B2 inhibition of focal adhesion kinase or/and IGF-1 Receptor; for example: 2-[2-(2,5-Dimethoxy-phenylamino)-5-nitro-pyrimidin-4-ylamino]-N-methyl-benzenesulfonamide NOVARTIS AG (CH) 2011-02-22 US claimed
EP-2208721-A1 HISTONE DEACETYLASE INHIBITOR, COMPOSITION AND USE THEREOF Zhejiang Hisun Pharmaceutical Co. Ltd. (CN) 2010-07-21 EP claimed
WO-2005016894-A1 2, 4-PYRIMIDINEDIAMINES USEFUL IN THE TREATMENT OF NEOPLASTIC DISEASES, INFLAMMATORY AND IMMUNE SYSTEM DISORDERS NOVARTIS AG (CH) 2005-02-24 WO claimed
US-6846827-B1 Pyrimidine derivatives ASTRAZENECA AB (SE) 2005-01-25 US claimed
EP-1226126-B1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2005-01-05 EP claimed
EP-1226126-A1 PYRIMIDINE DERIVATIVES AstraZeneca AB (SE) 2002-07-31 EP claimed
US-20020058788-A1 Facile deprotection of Fmoc protected amino groups DISCOVERY PARTNERS INTERNATIONAL, INC. 2002-05-16 US claimed
WO-2001027089-A1 PYRIMIDINE DERIVATIVES ASTRAZENECA AB (SE) 2001-04-19 WO claimed
EP-0025109-B1 1-BENZOXEPIN-5(2H)-ONE DERIVATIVES AND THEIR SALTS, AND PROCESSES FOR THEIR PREPARATION Kali-Chemie Pharma GmbH (DE) 1985-05-15 EP claimed
EP-0024560-B1 3-AMINO-1-BENZOXEPINE DERIVATIVES AND THEIR SALTS, PROCESSES FOR THEIR PREPARATION AND MEDICAMENTS CONTAINING THEM Kali-Chemie Pharma GmbH (DE) 1983-04-13 EP claimed
US-4279904-A GASTROINTESTINAL DISORDERS KALI-CHEMIE PHARMA GMBH (DE) 1981-07-21 US claimed
US-4279905-A GASTROINTESTINAL DISORDERS KALI-CHEMIE PHARMA GMBH (DE) 1981-07-21 US claimed